Institut de Génétique et Développement de Rennes, UMR 6290 CNRS, Université de Rennes 1, Rennes, France; SFR Biosit UMS CNRS 3480/US INSERM 018, Rennes, France.
Institut des Sciences Chimiques de Rennes, UMR 6226 CNRS, Université de Rennes 1, Rennes, France.
Int J Pharm. 2017 Nov 5;532(2):813-824. doi: 10.1016/j.ijpharm.2017.07.075. Epub 2017 Jul 29.
A number of nanoparticles has been developed by chemists for biomedical applications to meet imaging and targeting needs. In parallel, adoptive T therapy with chimeric antigen receptor engineered T cells (CART cells) has recently held great promise in B-cell malignancy treatments thanks to the development of anti-CD19 CAR T cells. Indeed, CD19 is a reliable B cell marker and a validated target protein for therapy. In this perspective article, we propose to discuss the advantages, limits and challenges of nanoparticles and CAR T cells, focusing on CD19 targeting objects: anti-CD19 nanoparticles and anti-CD19 CAR T cells, because those genetically-modified cells are the most widely developed in clinical setting. In the first part, we will introduce B cell malignancies and the CD19 surface marker. Then we will present the positioning of nanomedicine in the topic of B cell malignancy, before exposing CAR T technology. Finally, we will discuss the complementary approaches between nanoparticles and CAR T cells.
已经有许多化学家开发了用于生物医学应用的纳米颗粒，以满足成像和靶向需求。与此同时，嵌合抗原受体修饰的 T 细胞（CAR-T 细胞）过继性 T 疗法最近在 B 细胞恶性肿瘤治疗中展现出巨大的前景，这要归功于抗 CD19 CAR-T 细胞的发展。事实上，CD19 是一种可靠的 B 细胞标志物，也是治疗的验证靶蛋白。在这篇观点文章中，我们建议讨论纳米颗粒和 CAR-T 细胞的优势、限制和挑战，重点讨论针对 CD19 的靶向目标：抗 CD19 纳米颗粒和抗 CD19 CAR-T 细胞，因为这些基因修饰的细胞是临床研究中最广泛开发的。在第一部分，我们将介绍 B 细胞恶性肿瘤和 CD19 表面标志物。然后，我们将介绍纳米医学在 B 细胞恶性肿瘤研究中的定位，再介绍 CAR-T 技术。最后，我们将讨论纳米颗粒和 CAR-T 细胞之间的互补方法。
